Data protection Impressum

Bioinformatics

As life sciences companies navigate increasingly complex global markets, the decision of where to establish or expand international operations has become a strategic one.

Why Switzerland

Why Life Sciences Companies Choose Switzerland to Scale Internationally

Adaptyv raises USD 8 million to accelerate AI-powered protein validation

27 October 2025

A new automated platform developed by cellvie and CSEM streamlines mitochondria isolation, advancing therapeutic transplantation for ischemia-reperfusion injury.

CSEM and cellvie automate mitochondria isolation for clinical use

9 September 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (February 2025)

25 February 2025

The Swiss Institute of Bioinformatics has inaugurated the Centre for Pathogen Bioinformatics in Bern, a state-of-the-art facility dedicated to strengthening genomic surveillance of infectious diseases.

The Centre for Pathogen Bioinformatics was inaugurated in Bern

4 February 2025

The Swiss Institute of Bioinformatics has inaugurated its Centre for Pathogen Bioinformatics in Lausanne to enhance pathogen research and surveillance.

SIB launches the Centre for Pathogen Bioinformatics to strengthen global pandemic response

28 October 2024

The FONGIT Innovation Fund has awarded funding to three cutting-edge tech projects: CHF 100,000 seed loans for returning winners Planeto and HekeTiss, and a CHF 50,000 grant for newcomer LightEye.

CERN and UNIGE spin-offs awarded FIF Funding

2 July 2024

This CHF 18 million initiative focuses on developing artificial intelligence-guided neuromodulation therapies to treat neurologic and mental health disorders.

Wyss Center launches Lighthouse Partnership with key institutions from Western Switzerland

29 January 2024

BioLizard’s move to Lausanne reflects its growing international presence and dedication to serving the Swiss biotech industry.

Bioinformatics specialist BioLizard opens a new office at the Biopôle in Lausanne

24 January 2024

Vaccines unique to each patient and cancer are being tested at the CHUV

1 March 2022

1 2